Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.
Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.
复制标题
DOI：
10.1016/j.biopha.2021.111330
复制
发表时间：
2021-05
期刊：
影响因子：
--
通讯作者：
Zhang W
中科院分区：
文献类型：
--
作者：
Awadasseid A;Wu Y;Tanaka Y;Zhang W
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)是冠状病毒病2019年(新冠肺炎)的一个致病因素。药物再利用，将专利药物描述为一种成功的药物开发技术，与从头开始的药物探索相比，可以缩短周期并最大限度地降低成本。目前已有雷米昔韦、法维拉韦、羟氯喹、阿奇霉素、洛匹那韦/利托那韦、甲磺酸那法莫斯特等药物用于抗SARS-CoV-2。尽管作出了这些努力，但目前还没有成功的广谱抗病毒对策来抗击SARS-CoV-2或可能的CoVS大流行。因此，现在和将来认识和测试广泛有效、可靠的抗冠状病毒疗法是极其重要的。雷米西韦和法比拉韦尽管有副作用，但更有希望；它具有突出的疗效和效率，但仍未被批准为治疗SARS CoV-2的官方抗病毒药物。在这篇综述中，我们总结了目前针对SARS-CoV-2的药物和疫苗的发现状况，预测这些努力将有助于创造有效的SARS-CoV-2药物和疫苗。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a causal factor of the coronavirus disease 2019 (COVID-19). Drug repurposing, portraying patented drugs as a successful drug development technique, could shorten the period and minimize costs relative to de novo drug exploration. Recently several drugs have been used as anti-SARS-CoV-2 such as Remdesivir, Favipiravir, Hydroxychloroquine, Azithromycin, Lopinavir/Ritonavir, Nafamostat mesylate and so on. Despite such efforts, there is currently no successful broad-spectrum antiviral countermeasures to combat SARS-CoV-2 or possibly potential CoVs pandemic. Therefore it is desperately important to recognize and test widely efficient, reliable anti-CoV therapies now and in the future. Remdesivir and Favipiravir were more promising despite having side effects; it had prominent efficacy and efficiency while still not yet approved as the official anti-viral drug for SARS CoV-2. In this review, we summarizes the current drug and vaccine discovery status against SARS-CoV-2, predicting that these efforts will help create effective drugs and vaccines for SARS-CoV-2.
登录
查看更多内容
影响因子：
9.2
作者：
Awadasseid A;Wu Y;Tanaka Y;Zhang W
通讯作者：
Zhang W
影响因子：
7.6
作者：
Brown, Ariane J.;Won, John J.;Sheahan, Timothy P.
通讯作者：
Sheahan, Timothy P.
影响因子：
14.2
作者：
Chen, Chih-Lung;Wang, Shulhn-Der;Wang, Jiu-Yao
通讯作者：
Wang, Jiu-Yao
影响因子：
3.8
作者：
Andreani, Julien;Le Bideau, Marion;Raoult, Didier
通讯作者：
Raoult, Didier
影响因子：
10
作者：
Chu, CM;Cheng, VCC;Yuen, KY
通讯作者：
Yuen, KY